1. Search Result
Search Result
Targets Recommended: NADPH Oxidase
Results for "

NAD(P)H

" in MCE Product Catalog:

36

Inhibitors & Agonists

1

Screening Libraries

1

Dye Reagents

1

Biochemical Assay Reagents

8

Peptides

6

Natural
Products

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas
  • HY-F0003
    NADPH tetrasodium salt

    Ferroptosis Endogenous Metabolite Cancer
    NADPH tetrasodium salt functions as an important cofactor in a variety of metabolic and biosynthetic pathways. NADPH tetrasodium salt plays a vital role in the biosynthesis of drugs, chiral alcohols, fatty acids and biopolymers, while also being required for lipid biosynthesis, biomass formation, and cell replication. The demand for NADPH tetrasodium salt is particularly high in proliferating cancer cells, where it acts as a cofactor for the synthesis of nucleotides, proteins, and fatty acids. NADPH tetrasodium salt is also essential for the neutralization of the dangerously high levels of reactive oxygen species (ROS) generated by increased metabolic activity. NADPH tetrasodium salt is an endogenous inhibitor of ferroptosis.
  • HY-F0003A
    NADPH tetracyclohexanamine

    Ferroptosis Others
    NADPH tetracyclohexanamine is a ubiquitous cofactor and biological reducing agent.
  • HY-125027
    Isobutyl-deoxynyboquinone

    IB-DNQ

    Others Cancer
    Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1). Isobutyl-deoxynyboquinone can be used for the research of anticancer.
  • HY-113325
    NADP

    Endogenous Metabolite Others
    NADP, a nicotinamide adenine dinucleotide, is a redox cofactor. NADP is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH).
  • HY-F0002
    NADP sodium salt

    Sodium NADP

    Others Others
    NADP sodium salt (Sodium NADP), a nicotinamide adenine dinucleotide, is a redox cofactor. NADP sodium salt is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH).
  • HY-D0937
    Methoxy-PMS

    1-Methoxy PMS; 1-Methoxyphenazine methosulfate

    Reactive Oxygen Species Others
    Methoxy-PMS (1-Methoxy PMS), an active oxygen formation inducer, is stable electron-transport mediator between NAD(P)H and tetrazolium dyes.
  • HY-12804
    VAS2870

    NADPH Oxidase Cardiovascular Disease
    VAS2870 is a NADPH oxidase (NOX) inhibitor.
  • HY-F0002A
    NADP disodium salt

    Disodium NADP

    Others Others
    NADP disodium salt (Disodium NADP), a nicotinamide adenine dinucleotide, is a redox cofactor. NADP disodium salt is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH).
  • HY-N0088
    Apocynin

    Acetovanillone

    Autophagy Apoptosis Cancer
    Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM.
  • HY-18950
    GSK2795039

    NADPH Oxidase Reactive Oxygen Species Apoptosis Cancer
    GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 reduces apoptosis.
  • HY-107855
    DL-Mevalonolactone

    (±)-Mevalonolactone; Mevalolactone

    Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (∆Ψm), NAD(P)H content and the capacity to retain Ca 2+ in the brain, besides inducing mitochondrial swelling.
  • HY-12298
    Setanaxib

    GKT137831; GKT831

    NADPH Oxidase Ferroptosis Cardiovascular Disease
    Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.
  • HY-100965
    Diphenyleneiodonium chloride

    DPI

    TRP Channel NADPH Oxidase Reactive Oxygen Species Inflammation/Immunology Neurological Disease
    Diphenyleneiodonium chloride is a NADPH oxidase (NOX) inhibitor and also functions as a TRPA1 activator with an EC50 of 1 to 3 μM. Diphenyleneiodonium chloride selectively inhibits intracellular reactive oxygen species.
  • HY-N0645
    Dicoumarol

    Dicumarol

    PDHK Cancer
    Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and PDK1 with IC50s of 0.37 and 19.42 μM, respectively.
  • HY-100111
    GLX351322

    NADPH Oxidase Metabolic Disease
    GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
  • HY-108537
    L 012 sodium salt

    Others Inflammation/Immunology
    L 012 sodium salt a luminol-based chemiluminescent (CL) probe, is widely used in vitro and in vivo to detect NADPH oxidase (Nox)-derived superoxide (O2 •−) and identify Nox inhibitors.
  • HY-103667
    2-HBA

    Caspase Cancer
    2-HBA is a potent inducer of NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) which can also activate caspase-3 and caspase-10.
  • HY-116482
    Desmedipham

    Others Others
    Desmedipham is a selective systemic phenyl-carbamate herbicide. Desmedipham acts by disrupting CO2 fixation and the production of intermediary energy components-ATP and NADPH2 and inhibition of Hill reaction.
  • HY-W015422
    1,5-Isoquinolinediol

    PARP Metabolic Disease
    1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC50 of 0.18-0.37 µM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina.
  • HY-N0699
    Daphnoretin

    Dephnoretin; Thymelol

    PKC Influenza Virus Infection
    Daphnoretin (Dephnoretin), isolated from Wikstroemia indica, possesses antiviral activity. Daphnoretin likes PMA, may direct activation of protein kinase C which in turn activated NADPH oxidase and elicited respiratory burst.
  • HY-12803
    Fulvene-5

    NADPH Oxidase Reactive Oxygen Species Cancer
    Fulvene-5 is a potent NADPH oxidase 4 (NOX4) inhibitor with antioxidant properties. Fulvene-5 is a reactive oxygen species (ROS) modifying agent and a potent radioprotector. Fulvene-5 has antitumor activity.
  • HY-W004520
    Phenazine methylsulfate

    5-Methylphenazinium methylsulfate

    Bacterial Antibiotic Apoptosis Others
    Phenazine methylsulfate is a free radical generator. Phenazine methylsulfate has been used as an electron transfer reactant in cell viability assays. Phenazine methylsulfate induces ssDNA break formation in the presence of the reducing agent NADPH. Phenazine methylsulfate induces oxidative DNA damage in an alkaline comet assay and apoptosis.
  • HY-12805
    ML171

    2-Acetylphenothiazine; 2-APT

    NADPH Oxidase Cardiovascular Disease
    ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC50 of 0.25 μM in HEK293-Nox1 confirmatory assay.
  • HY-100986
    L-NIO dihydrochloride

    NO Synthase Cardiovascular Disease
    L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats.
  • HY-120801
    APX-115

    Ewha-18278

    NADPH Oxidase Metabolic Disease Inflammation/Immunology
    APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury.
  • HY-P1435
    NoxA1ds

    NADPH Oxidase Cardiovascular Disease
    NoxA1ds is a highly efficacious and selective Nox1 (NADPH oxidase isoform 1) inhibitor. NoxA1ds establishes a critical interaction site for Nox1-NOXA1 binding required for enzyme activation. NoxA1ds can be used for the research of hypertension, atherosclerosis and neoplasia.
  • HY-101499A
    GKT136901 hydrochloride

    NADPH Oxidase Metabolic Disease Neurological Disease
    GKT136901 hydrochloride is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 hydrochloride is also a selective and direct scavenger of peroxynitrite. GKT136901 hydrochloride can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 hydrochloride also has anti-inflammatory activity.
  • HY-121246
    Fluorofenidone

    AKF-PD

    Others Inflammation/Immunology
    Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway.
  • HY-101499
    GKT136901

    NADPH Oxidase Metabolic Disease Inflammation/Immunology Neurological Disease
    GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity.
  • HY-120801A
    APX-115 free base

    Ewha-18278 free base

    NADPH Oxidase Endocrinology Inflammation/Immunology
    APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury.
  • HY-13543
    Tretazicar

    CB 1954

    DNA Alkylator/Crosslinker Cancer
    Tretazicar (CB 1954), an antitumor prodrug, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1).
  • HY-128895
    KL1333

    Mitochondrial Metabolism Metabolic Disease
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures.
  • HY-12119A
    GW274150 phosphate

    NO Synthase Inflammation/Immunology Neurological Disease
    GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation.
  • HY-12119
    GW274150

    NO Synthase Inflammation/Immunology Neurological Disease
    GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation.
  • HY-14572
    PR-104A

    SN 27858

    DNA Alkylator/Crosslinker Cancer
    PR-104A (SN 27858) is the alcohol metabolite of phosphate prodrug PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity. PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL).
  • HY-P1435A
    NoxA1ds TFA

    NADPH Oxidase
    NoxA1ds TFA is a potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds TFA exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. NoxA1ds TFA inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro.